Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 6/2014

01-12-2014 | Review Article

Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine

Authors: Rosa I. Gallagher, Virginia Espina

Published in: Molecular Diagnosis & Therapy | Issue 6/2014

Login to get access

Abstract

Reverse phase protein array (RPPA) technology evolved from the advent of miniaturized immunoassays and gene microarray technology. Reverse phase protein arrays provide either a low throughput or high throughput methodology for quantifying proteins and their post-translationally modified forms in both cellular and non-cellular samples. As the demand for patient tailored therapies increases so does the need for precise and sensitive technology to accurately profile the molecular circuitry driving an individual patient’s disease. RPPAs are currently utilized in clinical trials for profiling and comparing the functional state of protein signaling pathways, either temporally within tumors, between patients, or within the same patients before/after treatment. RPPAs are generally employed for quantifying large numbers of samples on one array, under identical experimental conditions. However, the goal of personalized cancer medicine is to design therapies based on the molecular portrait of a patient’s tumor, which in turn result in more efficacious treatments with less toxicity. Therefore, RPPAs are also being validated for low throughput assays of individual patient samples. This review explores RPPA technology in the cancer research field, concentrating on its role as a fundamental tool for deciphering protein signaling networks and its emerging role in personalized medicine.
Literature
1.
Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286(18):2211–4.PubMedCrossRef
2.
Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1(9):683–95.PubMedCrossRef
3.
de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467(7315):543–9.PubMedCrossRef
4.
Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201–4.PubMedCrossRef
5.
Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147(3):579–88.PubMedCrossRef
6.
7.
Patel LR, Nykter M, Chen K, Zhang W. Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution. Cancer Lett. 2013;340(2):152–60.PubMedCrossRef
8.
Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics. 2003;3(11):2091–100.PubMedCrossRef
9.
Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3(4):317–25.PubMedCrossRef
10.
Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005;23(15):3614–21.PubMedCrossRef
11.
Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004;40(17):2623–32.PubMedCrossRef
12.
Chen LC, Elliott RA, Ashcroft DM. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. J Clin Pharm Ther. 2004;29(3):215–29.PubMedCrossRef
13.
Desjardins PJ, Mehlisch DR, Chang DJ, Krupa D, Polis AB, Petruschke RA, et al. The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trials. Clin J Pain. 2005;21(3):241–50.PubMedCrossRef
14.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.PubMed
15.
Labianca R, Pancera G, Luporini G. Factors influencing response rates for advanced colorectal cancer chemotherapy. Ann Oncol. 1996;7(9):901–6.PubMedCrossRef
16.
Moreau LC, Rajan R, Thirlwell MP, Alcindor T. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Anticancer Res. 2013;33(4):1765–8.PubMed
17.
Advanced colorectal cancer meta-analysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10(6):896–903.
18.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626–34.PubMedCrossRef
19.
Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.PubMedCrossRef
20.
Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, et al. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One. 2010;5(4):e10240.PubMedCentralPubMedCrossRef
21.
Petricoin EF 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67(7):3431–40.PubMedCrossRef
22.
Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, et al. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab. J Proteome Res. 2014;13(6):2846–55.PubMedCrossRef
23.
Akbani R, Becker KF, Carragher N, Goldstein T, de Koning L, Korf U, et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (reverse phase protein array) society. Mol Cell Proteomics. 2014;13(7):1625–43.PubMedCrossRef
24.
Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. Methods Mol Biol. 2007;383:321–36.PubMed
25.
26.
Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003;63(17):5243–50.PubMed
27.
Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics Proteomics. 2007;4(3):157–64.PubMed
28.
Davuluri G, Espina V, Petricoin EF 3rd, Ross M, Deng J, Liotta LA, et al. Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. Arch Ophthalmol. 2009;127(5):613–21.PubMedCentralPubMedCrossRef
29.
Popova TG, Turell MJ, Espina V, Kehn-Hall K, Kidd J, Narayanan A, et al. Reverse-phase phosphoproteome analysis of signaling pathways induced by Rift valley fever virus in human small airway epithelial cells. PLoS One. 2010;5(11):e13805.PubMedCentralPubMedCrossRef
30.
Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20(16):1981–9.PubMedCrossRef
31.
Bobrow MN, Harris TD, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods. 1989;125(1–2):279–85.PubMedCrossRef
32.
Bobrow MN, Shaughnessy KJ, Litt GJ. Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods. 1991;137(1):103–12.PubMedCrossRef
33.
King G, Payne S, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol. 1997;183(2):237–41.PubMedCrossRef
34.
35.
VanMeter A, Signore M, Pierobon M, Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn. 2007;7(5):625–33.PubMedCrossRef
36.
Espina V, Petricoin E, Liotta L, Geho D. Application of sector protein microarrays to clinical samples. Clin Proteomics. 2004;1(91):91–9.CrossRef
37.
Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics. 2004;4(12):3665–85.PubMedCrossRef
38.
Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta. 2005;357(2):180–3.PubMedCrossRef
39.
Gulmann C, Espina V, Petricoin E 3rd, Longo DL, Santi M, Knutsen T, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res. 2005;11(16):5847–55.PubMedCrossRef
40.
Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008;7(4):1508–17.PubMedCrossRef
41.
Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008;7(10):1998–2018.PubMedCentralPubMedCrossRef
42.
Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis. 2000;21(11):2235–42.PubMedCrossRef
43.
van Oostrum J, Calonder C, Rechsteiner D, Ehrat M, Mestan J, Fabbro D, et al. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin Appl. 2009;3(4):412–22.PubMedCrossRef
44.
VanMeter AJ, Rodriguez AS, Bowman ED, Jen J, Harris CC, Deng J, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 2008;7(10):1902–24.PubMedCentralPubMedCrossRef
45.
Gallagher RI, Silvestri A, Petricoin EF 3rd, Liotta LA, Espina V. Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol. 2011;723:275–301.PubMedCrossRef
46.
Pin E, Federici G, Petricoin EF 3rd. Preparation and use of reverse protein microarrays. Curr Protoc Protein Sci. 2014;75:27.7.1–27.7.29.
47.
Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012;18(23):6426–35.PubMedCrossRef
48.
Chiechi A, Mueller C, Boehm KM, Romano A, Benassi MS, Picci P, et al. Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. Biotechniques. 2012;53(3):1–7.
49.
Troncale S, Barbet A, Coulibaly L, Henry E, He B, Barillot E, et al. NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One. 2012;7(6):e38686.PubMedCentralPubMedCrossRef
50.
Eichner J, Heubach Y, Ruff M, Kohlhof H, Strobl S, Mayer B, et al. RPPApipe: a pipeline for the analysis of reverse-phase protein array data. Biosystems. 2014;122:19–24.PubMedCrossRef
51.
Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci. 2003;100(24):14229–34.PubMedCentralPubMedCrossRef
52.
von der Heyde S, Sonntag J, Kaschek D, Bender C, Bues J, Wachter A, et al. RPPanalyzer Toolbox: an improved R package for analysis of reverse phase protein array data. Biotechniques. 2014;57(3):125–35.PubMed
53.
Mueller C, deCarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V, et al. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res. 2014;74(3):818–28.PubMedCrossRef
54.
Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest. 2010;90(5):787–96.PubMedCrossRef
55.
Mukherjee S, Rodriguez-Canales J, Hanson J, Emmert-Buck MR, Tangrea MA, Prieto DA, et al. Proteomic analysis of frozen tissue samples using laser capture microdissection. Methods Mol Biol. 2013;1002:71–83.PubMedCrossRef
56.
Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, et al. Laser capture microdissection: molecular analysis of tissue. Science. 1997;278(5342):1481–3.PubMedCrossRef
57.
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996;274(5289):998–1001.PubMedCrossRef
58.
Espina V, Wulfkuhle J, Liotta LA. Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. Clin Lab Med. 2009;29(1):1–13.PubMedCrossRef
59.
Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. Nat Protoc. 2006;1(2):586–603.PubMedCrossRef
60.
Gallagher RI, Blakely SR, Liotta LA, Espina V. Laser capture microdissection: arcturus(XT) infrared capture and UV cutting methods. Methods Mol Biol. 2012;823:157–78.PubMedCrossRef
61.
Xu BJ. Combining laser capture microdissection and proteomics: methodologies and clinical applications. Proteomics Clin Appl. 2010;4(2):116–23.PubMedCrossRef
62.
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.PubMedCrossRef
63.
Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, et al. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 2013;32(29):3470–6.PubMedCentralPubMedCrossRef
64.
Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, et al. The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer. 2007;111(3):173–84.PubMedCrossRef
65.
Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005;4(4):346–55.PubMedCrossRef
66.
Sheehan KM, Gulmann C, Eichler GS, Weinstein JN, Barrett HL, Kay EW, et al. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene. 2008;27(3):323–31.PubMedCrossRef
67.
Li J, Gould TD, Yuan P, Manji HK, Chen G. Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology. 2003;28(6):1017–25.PubMedCrossRef
68.
Li X, Friedman AB, Roh MS, Jope RS. Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem. 2005;92(3):701–4.PubMedCentralPubMedCrossRef
69.
Espina V, Mueller C, Edmiston K, Sciro M, Petricoin EF, Liotta LA. Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl. 2009;3(8):874–82.PubMedCentralPubMedCrossRef
70.
Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One. 2011;6(8):e23780.PubMedCentralPubMedCrossRef
71.
Grellner W, Madea B. Demands on scientific studies: vitality of wounds and wound age estimation. Forensic Sci Int. 2007;165(2–3):150–4.PubMedCrossRef
72.
Goldstein BJ. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab. 2002;87(6):2474–80.PubMedCrossRef
73.
Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol. 1997;9(2):193–204.PubMedCrossRef
74.
Liotta LA, Petricoin EF 3rd. Omics and cancer biomarkers: link to the biological truth or bear the consequences. Cancer Epidemiol Biomark Prev. 2012;21(8):1229–35.CrossRef
75.
Tell RW, Horvath CM. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. Proc Natl Acad Sci. 2014;111(35):12787–92.PubMedCrossRef
76.
Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8.PubMedCrossRef
77.
He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W, Guo C, et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012;7(2):e31087.PubMedCentralPubMedCrossRef
78.
Angenendt P. Progress in protein and antibody microarray technology. Drug Discov Today. 2005;10(7):503–11.PubMedCrossRef
79.
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242–9.PubMedCentralPubMedCrossRef
80.
81.
Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin EF 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol. 2006;208(5):595–606.PubMedCrossRef
82.
Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Technology insight: pharmacoproteomics for cancer–promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006;3(5):256–68.PubMedCrossRef
83.
Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK Jr, Jones AR, et al. The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol. 2007;25(8):887–93.PubMedCrossRef
Metadata
Title
Reverse Phase Protein Arrays: Mapping the Path Towards Personalized Medicine
Authors
Rosa I. Gallagher
Virginia Espina
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 6/2014
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-014-0122-3

Other articles of this Issue 6/2014

Molecular Diagnosis & Therapy 6/2014 Go to the issue

Review Article

Review of the Prognostic Value of Galectin-3 in Heart Failure Focusing on Clinical Utility of Repeated Testing

Original Research Article

Pyrosequencing for Classification of Human FcγRIIIA Allotypes: A Comparison with PCR-Based Techniques

Original Research Article

Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study

Acknowledgement to Referees

Acknowledgement to Referees

Original Research Article

Stabilization of Cellular RNA in Blood During Storage at Room Temperature: A Comparison of Cell-Free RNA BCT® with K3EDTA Tubes

Short Communication

Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits